Freedman, Rachel A.
Seisler, D. K.
Foster, J. C.
Sloan, J. A.
Lafky, J. M.
Kimmick, G. G.
Hurria, A.
Cohen, H. J.
Winer, E. P.
Hudis, C. A.
Partridge, A. H.
Carey, L. A.
Jatoi, A.
Klepin, H. D.
Citron, M.
Berry, D. A.
Shulman, L. N.
Buzdar, A. U.
Suman, V. J.
Muss, H. B.
Funding for this research was provided by:
Susan G. Komen for the Cure (CCR14298143)
American Cancer Society (125912-MRSG-14-240-01-CPPB)
National Cancer Institute (UG1CA189823, U10CA032291, U10CA047559, U10CA047577, U10CA077597, U10CA077651, U10CA180790, U10CA180791, U10CA180838, U10CA180857, U10CA180867)
Article History
Received: 4 November 2016
Accepted: 5 November 2016
First Online: 19 November 2016
Compliance with ethical standards
:
: Rachel Freeman has received institutional funding from Genentech, Puma, and Eisai. Drew Seisler reports renumeration from Mayo Clinic. Jared Foster declares that he has no conflict of interest. Jeff Sloan declares that he has no conflict of interest. Jacqueline Lafky declares that she has no conflict of interest. Gretchen Kimmick has served on speakers bureaus and has consultant/advisory roles for Pfizer, Astra Zeneca, Novartis, Genomic Health, and Genentech, and has received funding from Wyeth, Astra Zeneca, Glaxo Smith Kline, Novartis, PUMA, Bristol Meyers Squibb, and Bionovo. Arti Hurria has consultant/advisory roles for Boehringer Ingelheim Pharmaceuticals, Carevive, Sanofi, and GTx, Inc, and has received funding from Celegene, Novartis, and GSK. Harvey Cohen declares that he has no conflict of interest. Eric Winer declares that he has no conflict of interest. Clifford Hudis declares that he has no conflict of interest. Ann Partridge declares that she has no conflict of interest. Lisa Carey declares that she has no conflict of interest. Aminah Jatoi declares that he has no conflict of interest. Heidi Klepin declares that she has no conflict of interest. Marc Citron reports speakers bureau roles for Genentech and Pfizer, consultant/advisory roles for Genentech and Pfizer, and funding from Genentech, Pfizer, Celldex, Merck, Puma, and Macrogenics. Donald Berry reports renumeration from Berry Consultants, LLC, a consultant/advisory role for Berry Consultants, LLC, and stock ownership in Berry Consultants, LLC (co-owner). Lawrence Shulman declares that he has no conflict of interest. Aman Buzdar declares that he has no conflict of interest. Vera Suman declares that she has no conflict of interest. Hyman Muss declares that he has no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors. The manuscript only includes secondary analysis of pre-existing data that were collected as part of the included clinical trials.